Drug Development Pipeline
Restore CFTR Function
This program is developing potential CFTR modulators, a type of drug designed to fix the defective CFTR protein. These new modulators could benefit people with the most common CF-causing mutation, F508del, and may eventually offer an alternative to currently approved modulators.
Laboratory studies to develop and test these compounds are underway.
This program is sponsored by Sionna Therapeutics and partially funded by the Cystic Fibrosis Foundation.
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.Learn More